Literature DB >> 6860201

Use of betaxolol in the reduction of elevated intraocular pressure.

R L Radius.   

Abstract

Forty eyes in 20 patients with elevated intraocular pressure were treated with either a 0.125% betaxolol ophthalmic solution or a placebo. After 2, 4, and 6 weeks of twice-daily therapy, the eyes receiving the betaxolol had a mean percent reduction in IOP greater than that in the eyes treated only with the drug vehicle (placebo). Both solutions were well tolerated.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6860201     DOI: 10.1001/archopht.1983.01040010898008

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  6 in total

Review 1.  Pharmacological therapy for glaucoma: a review.

Authors:  P F Hoyng; L M van Beek
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

Review 2.  Ocular betaxolol. A review of its pharmacological properties, and therapeutic efficacy in glaucoma and ocular hypertension.

Authors:  M M Buckley; K L Goa; S P Clissold
Journal:  Drugs       Date:  1990-07       Impact factor: 9.546

Review 3.  Ocular beta-blockers in glaucoma management. Clinical pharmacological aspects.

Authors:  A M Brooks; W E Gillies
Journal:  Drugs Aging       Date:  1992 May-Jun       Impact factor: 3.923

4.  Levobetaxolol hydrochloride: a review of its pharmacology and use in the treatment of chronic open-angle glaucoma and ocular hypertension.

Authors:  Luciano Quaranta; Raffaele Turano; Teodoro Pizzolante
Journal:  Clin Ophthalmol       Date:  2007-06

5.  Effects of topical timolol (0.5%) and betaxolol (0.5%) on corneal sensitivity.

Authors:  S S Weissman; P A Asbell
Journal:  Br J Ophthalmol       Date:  1990-07       Impact factor: 4.638

6.  A Randomized, Double-Masked, Active-Controlled, Crossover Phase III Equivalence Study of Generic Dorzolamide 2% versus Innovator Trusopt® Eye Drop Solution in Subjects with Open-Angle Glaucoma or Ocular Hypertension.

Authors:  Katharina Bell; Christina Korb; Christina Butsch; Bert Constantin Giers; Anna Beck; Alicja Strzalkowska; Christian Ruckes; Ulrike Klingberg; Norbert Pfeiffer; Katrin Lorenz
Journal:  J Ophthalmol       Date:  2022-07-20       Impact factor: 1.974

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.